[HTML][HTML] An observational study of matrix metalloproteinase (MMP)-9 in cystic fibrosis
G Devereux, S Steele, T Jagelman, S Fielding… - Journal of Cystic …, 2014 - Elsevier
G Devereux, S Steele, T Jagelman, S Fielding, R Muirhead, J Brady, C Grierson, R Brooker…
Journal of Cystic Fibrosis, 2014•ElsevierBackground In cystic fibrosis (CF), cross-sectional studies have reported sputum matrix
metalloproteinase (MMP)-9 to be elevated and negatively correlated with FEV 1. This
longitudinal study examined the association between MMP-9 and tissue inhibitors of
metalloproteinases (TIMPs) to prognostic parameters in CF. Method A cross-sectional
survey of CF and control subjects; CF patients were followed up for a median of 49 months.
MMP-9 and TIMP-1 and TIMP-2 were quantified in sputum and plasma. Results Seventy …
metalloproteinase (MMP)-9 to be elevated and negatively correlated with FEV 1. This
longitudinal study examined the association between MMP-9 and tissue inhibitors of
metalloproteinases (TIMPs) to prognostic parameters in CF. Method A cross-sectional
survey of CF and control subjects; CF patients were followed up for a median of 49 months.
MMP-9 and TIMP-1 and TIMP-2 were quantified in sputum and plasma. Results Seventy …
Background
In cystic fibrosis (CF), cross-sectional studies have reported sputum matrix metalloproteinase (MMP)-9 to be elevated and negatively correlated with FEV1. This longitudinal study examined the association between MMP-9 and tissue inhibitors of metalloproteinases (TIMPs) to prognostic parameters in CF.
Method
A cross-sectional survey of CF and control subjects; CF patients were followed up for a median of 49 months. MMP-9 and TIMP-1 and TIMP-2 were quantified in sputum and plasma.
Results
Seventy-three patients with CF, median age 22 years, and 40 controls were recruited. Fifty-three of these CF patients were followed up. Prospectively, in CF subjects, plasma MMP-9 activity was adversely associated with FEV1 (β − 1.15 (95% CI − 2.10, − 0.20), p = 0.019) and rate of FEV1 decline, and plasma TIMP-1 was adversely associated with mortality: hazard ratio 3.66 (1.91–7.04), p < 0.001.
Conclusions
These associations further justify investigation of MMP-9 and TIMP-1 as biomarkers for short- to medium-term FEV1 decline and mortality in patients with CF.
Elsevier